These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 485425)

  • 21. Cyclical combination chemotherapy in advanced breast cancer.
    Edelstyn GA; Marcrae KD
    Ann R Coll Surg Engl; 1974 Jun; 54(6):275-6. PubMed ID: 4833779
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant chemotherapy with four drugs for stage 2 breast cancer.
    Wheeler TK; Edelstyn GA; Bates TS; Brinkley D; Evans RG; Kitchen G; MacRae KD; Nicol NT; Spittle M; Wheeler TK
    Eur J Cancer (1965); 1980; Suppl 1():161-3. PubMed ID: 7032926
    [No Abstract]   [Full Text] [Related]  

  • 23. A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.
    Bull JM; Tormey DC; Li SH; Carbone PP; Falkson G; Blom J; Perlin E; Simon R
    Cancer; 1978 May; 41(5):1649-57. PubMed ID: 348293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current overview of EORTC clinical trials with tamoxifen.
    Heuson JC
    Cancer Treat Rep; 1976 Oct; 60(10):1463-6. PubMed ID: 1021227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combination chemotherapy with cyclophosphamide, methotrexate, 5-fluoro-uracil, and vincristine in solid metastasized tumours (author's transl)].
    Castor H; Fritsch H; Drings P; Moskwa G; von Kaick G
    Med Klin; 1974 Apr; 69(17):750-6. PubMed ID: 4837493
    [No Abstract]   [Full Text] [Related]  

  • 26. CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial.
    Mouridsen HT; Palshof T; Engelsman E; Sylvester R
    Eur J Cancer (1965); 1980; Suppl 1():119-23. PubMed ID: 7032921
    [No Abstract]   [Full Text] [Related]  

  • 27. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.
    Mortimer J; Livingston RB; Hardesty IJ; Groppe CW; Purvis JD; Gupta M; Flournoy N
    Cancer Treat Rep; 1984; 68(7-8):1017-8. PubMed ID: 6744334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of a prospective clinical trial comparing two cytotoxic regimes containing adriamycin in women with advanced breast cancer.
    Priestman TJ
    Clin Oncol; 1975 Sep; 1(3):207-11. PubMed ID: 1212828
    [No Abstract]   [Full Text] [Related]  

  • 29. The case for adjuvant CMF chemotherapy in breast cancer. Has it been made?
    Levitt SH; Potish RA
    Cancer Clin Trials; 1981; 4(4):363-9. PubMed ID: 7032731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy and breast cancer.
    N Z Med J; 1976 Jun; 83(565):409-10. PubMed ID: 1067486
    [No Abstract]   [Full Text] [Related]  

  • 31. [Management of advanced breast cancer in post-menopausal women. A comparative trial of hormonal therapy, chemotherapy, and a combination of both].
    Clavel B; Cappelaere JP; Guerin J; Klein T; Pommatau E; Berlie J
    Sem Hop; 1982 Sep; 58(34):1919-23. PubMed ID: 6293073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with adriamycin, cyclophosphamide and vicristine for advanced breast cancer supplemented with non cross-resistant combination.
    Jain SP; Pandey UC; Tandon US; Jain KK; Agarwal S
    Indian J Cancer; 1979; 16(3-4):43-6. PubMed ID: 540959
    [No Abstract]   [Full Text] [Related]  

  • 33. [Drug therapy of pulmonary metastases of breast cancer].
    Voznyĭ EK; Meshcheriakova NG; Melent'eva EG; Al'tshuler IuB
    Sov Med; 1990; (5):110-4. PubMed ID: 2389192
    [No Abstract]   [Full Text] [Related]  

  • 34. Adjuvant treatment in operable breast cancer.
    O'Brien PH
    J S C Med Assoc; 1976 May; 72(5):173-4. PubMed ID: 1063901
    [No Abstract]   [Full Text] [Related]  

  • 35. Doxorubicin in the treatment of advanced breast cancer; comparative studies of three combination chemotherapy regimes.
    Brown I; Ward HW
    Clin Oncol; 1976 Jun; 2(2):105-11. PubMed ID: 954258
    [No Abstract]   [Full Text] [Related]  

  • 36. Antitumor effect of combination of cyclophosphamide, adriamycin and platinum (CAP) versus cyclophosphamide, adriamycin and 5-fluorouracil (CAF) in metastatic breast cancer.
    Tzekova V; Velikova M; Koynov K; Micheva D; Donchev T
    Neoplasma; 1991; 38(6):603-7. PubMed ID: 1766485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cyclophosphamide, methotrexate and 5-fluorouracil (CMF), versus 5-fluorouracil, in carcinoma of the large intestine in an advanced stage].
    Scanni A; Tomirotti M; Biraghi M; Annibali E; Del Bianco S
    Minerva Med; 1980 Mar; 71(10):799-801. PubMed ID: 7360368
    [No Abstract]   [Full Text] [Related]  

  • 38. Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer.
    Eagan RT; Hahn RG; Myers RP
    Cancer Treat Rep; 1976 Jan; 60(1):115-7. PubMed ID: 1000515
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
    Bruckner HW; Deppe G
    Obstet Gynecol; 1977 Jul; 50(1 Suppl):10s-12s. PubMed ID: 876531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nursing the woman receiving adjuvant chemotherapy for breast cancer.
    Laatsch N
    Nurs Clin North Am; 1978 Jun; 13(2):337-49. PubMed ID: 248746
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.